Although targeted therapies against Class II alterations, Class III mutations, and BRAF rearrangements are largely still in early development, the accelerated approval of tovorafenib for patients with relapsed/refractory BRAF-altered pediatric low-grade glioma underscores the therapeutic potential of this and other next-generation strategies to target aberrant MAPK signaling. The gene discussed is BRAF; the disease is glioma.